Charles River Labs Files Additional Proxy Materials

TL;DR

CRL just dropped more proxy docs, likely updates for shareholders on upcoming votes.

AI Summary

Charles River Laboratories International, Inc. filed a Definitive Additional Materials proxy statement on April 24, 2024. This filing is related to the company's proxy solicitation materials, indicating it's providing supplementary information to shareholders regarding a meeting or vote. The filing does not contain specific financial figures or proposals but serves as an addendum to previously submitted proxy statements.

Why It Matters

This filing indicates that Charles River Laboratories is providing updated or supplementary information to its shareholders concerning matters to be voted on, which is crucial for informed shareholder participation.

Risk Assessment

Risk Level: low — This is a routine SEC filing for proxy materials and does not inherently present new financial or operational risks.

Key Players & Entities

• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — Registrant
• 0000950103-24-005647 (filing_id) — Accession Number
• 20240424 (date) — Filing Date

FAQ

Filing Documents

• dp210186_defa14a.htm (DEFA14A) — 34KB
• image_001.jpg (GRAPHIC) — 3KB
• 0000950103-24-005647.txt ( ) — 40KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material under §240.14a-12 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee paid previously with preliminary materials. o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SUPPLEMENT TO DEFINITIVE PROXY STATEMENT RELATING TO THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON FRIDAY, MAY 8, 2024 On March 29, 2024, Charles River Laboratories International, Inc. (“Charles River” or the “Company”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission, in connection with the Company’s Annual Meeting of Shareholders to be held on May 8, 2024. The Company is filing this supplement to the Proxy Statement (the “Supplement”) relating to our opposition to Proposal Four – Shareholder Proposal. Proposal Four in our 2024 Proxy Statement is substantially similar to the shareholder proposal by the same proponent included in our 2023 Proxy Statement that requested a report on non-human primates (NHPs) imported by the Company. In addition to information requested in the 2023 shareholder proposal, Proposal Four also requests zoonotic data. Based on the rationale described in the shareholder proposal in the Proxy Statement, and the additional information set forth in this supplement, the Board of Directors continues to recommend that shareholders vote “AGAINST” Proposal Four. THE PROXY STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. To our Shareholders, As a leading global non-clinical drug development partner, Charles River’s mission is to create healthier lives. We perform a vital role in the biopharmaceutical industry, providing essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe to discover, develop, test and safely manufacture new therapies. The success of our strategy is demonstrated by the fact that we have worked on more than 80% of the drugs approved by the U.S. Food and Drug Administration (FDA) over the last five years. Proposal Four in our 2024 Proxy Statement requests a report on non-human primates (NHPs) imported by the Company. As noted in the Proxy Statement, this proposal is not in the interests of the Company for the following reasons: • As we committed to shareholders in connection with the 2023 Annual Meeting, Charles River published in March 2024 the first annual report to shareholders on measures the Company takes to reinforce confidence that the NHPs we import are sourced in accordance with applicable laws (the “NHP Report”). The NHP Report may be accessed at the following link: www.criver.com/annual2024 . • At our 2023 Annual Meeting, the same proponent put forward a substantially similar proposal, which was unsuccessful. • The use of NHPs is fundamental to research and understanding on the prevention and treatment of emerging infectious diseases, as well as the development of new innovative treatments for cancer, diabetes, and a number of other diseases currently without effective treatment options. • Charles River is committed to ensuring that our operations are compliant with applicable U.S. and international laws and regulations related to animal transportation and welfare, including all required reporting elements. • The stewardship of the research animals in our care, including their humane care and well-being, is a core value of our Company. NHP Report Meets and Exceeds What is Requested in 2024 Shareholder Proposal Four The NHP Report focuses on concrete initiatives being implemented to reinforce confidence that NHPs the Company imports are sourced in accordance with applicable laws. The NHP Report includes the following information that specifically addresses all of the substantive, non-proprietary shareholder requests from Proposal Four, as well as additional content prompted by the feedback provided during our broader shareholder outreach on this topic: · Supply data on NHPs, including granular data on the global number of NHPs placed in studies by our Safety Assessmen

View Full Filing

View this DEFA14A filing on SEC EDGAR